Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2019 00:30 ET | Source: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

Akcea e Ionis reciben una opinión positiva del CHMP de la UE para WAYLIVRATM (volanesorsen)

BOSTON, Massachusetts, y CARLSBAD, California, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ: AKCA), una filial de Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals, Inc....
March 06, 2019 00:30 ET | Source: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

Akcea und Ionis erhalten positive Stellungnahme des CHMP zu WAYLIVRATM (Volanesorsen)

BOSTON, Massachusetts und CARLSBAD, Kalifornien, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), ein Tochterunternehmen von Ionis Pharmaceuticals, Inc. und Ionis...
March 01, 2019 07:45 ET | Source: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
February 28, 2019 07:00 ET | Source: Akcea Therapeutics, Inc.

Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
February 26, 2019 16:05 ET | Source: Akcea Therapeutics, Inc.

Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018

TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference...
February 25, 2019 01:15 ET | Source: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an...
February 20, 2019 07:00 ET | Source: Akcea Therapeutics, Inc.

Akcea Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
February 13, 2019 16:05 ET | Source: Akcea Therapeutics, Inc.

Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February...
November 29, 2018 07:00 ET | Source: Akcea Therapeutics, Inc.

Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the...
November 28, 2018 15:57 ET | Source: Akcea Therapeutics, Inc.

Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии.

Бостон, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии. Сообщество ставит целью повышения знаний в обществе о тяжести...